Urate‐lowering therapy in patients with hyperuricemia and heart failure: A retrospective cohort study using the UK Clinical Practice Research Datalink
Clinical Cardiology · 2024
DOI: 10.1002/clc.24297 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Cardiology, 2024. Verfasst von Steven J Kiddle und 4 weiteren Autor:innen. Beteiligte Einrichtung: Data Science & Advanced Analytics, Data Science & Artificial Intelligence, R&D, AstraZeneca, Cambridge, UK. Hauptthemen laut MEDLINE: Hyperuricemia, Heart Failure, Uric Acid, Gout Suppressants. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Elevated serum uric acid (sUA) is associated with heart failure (HF). Hypothesis Urate‐lowering therapy (ULT) in HF is associated with lower risk of HF hospitalization (hHF) and mortality.
Methods
Data on patients with HF and gout or hyperuricemia in the Clinical Practice Research Datalink database linked to the Hospital Episode Statistics and the Office for National Statistics in the United Kingdom were analyzed. Risks of hHF and all‐cause mortality or cardiovascular‐related mortality by ULT exposure (ULT initiated within ≤6 months of gout or hyperuricemia diagnosis) were analyzed in a propensity score‐matched cohort using adjusted Cox proportional hazards regression models.
Results
Of 2174 propensity score‐matched pairs, patients were predominantly male, aged >70 years, with mean ± standard deviation sUA 9.3 ± 1.8 (ULT‐exposed) and 9.4 ± 1.9 mg/dL (ULT‐unexposed). At 5 years, ULT‐exposed patients had a 43% lower risk of hHF or all‐cause mortality (adjusted hazard ratio [HR]: 0.57; 95% confidence interval [CI]: 0.51–0.65) and a 19% lower risk of hHF or cardiovascular‐related mortality (adjusted HR: 0.81; 95% CI: 0.71–0.92) versus no ULT exposure.
Conclusion
ULT was associated with reduced risk of adverse clinical outcomes in patients with HF and gout or hyperuricemia over 5 years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Data Science & Advanced Analytics, Data Science & Artificial Intelligence, R&D, AstraZeneca, Cambridge, UK.
- Cardiovascular, Renal and Metabolic (CVRM) Evidence, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden.
- Late-stage Development, Clinical, Cardiovascular, Renal and Metabolic (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
- Late-stage Development, Clinical, Cardiovascular, Renal and Metabolic (CVRM), BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
- Global Medical Affairs, Clinical, Cardiovascular, Renal and Metabolic (CVRM), BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden.
Förderung
- AstraZeneca
Zitieren
APA
Kiddle, S. J., Sundell, K. A., Perl, S., Nolan, S., & Bjursell, M. (2024). Urate‐lowering therapy in patients with hyperuricemia and heart failure: A retrospective cohort study using the UK Clinical Practice Research Datalink. Clinical Cardiology. https://doi.org/10.1002/clc.24297
Vancouver
Kiddle SJ, Sundell KA, Perl S, Nolan S, Bjursell M. Urate‐lowering therapy in patients with hyperuricemia and heart failure: A retrospective cohort study using the UK Clinical Practice Research Datalink. Clinical Cardiology. 2024. doi:10.1002/clc.24297
BibTeX
@article{Kiddle2024,
author = {Kiddle, Steven J and Sundell, Karolina Andersson and Perl, Shira and Nolan, Stephen and Bjursell, Magnus},
title = {Urate‐lowering therapy in patients with hyperuricemia and heart failure: A retrospective cohort study using the UK Clinical Practice Research Datalink},
journal = {Clinical Cardiology},
year = {2024},
doi = {10.1002/clc.24297}
}
EUVIMED